TapImmune is advancing two clinical-stage T-cell vaccine candidates in multiple Phase II and Phase Ib/IIa clinical trials, with ongoing clinical trials in ovarian and breast cancers. The U.S. market alone is very large for these cancers, with approx. 30,000 ovarian cancer patients, 40,000 triple negative breast cancer patients, and 220,000 Her2/neu breast cancer patients newly diagnosed with disease every year.
The current treatment options are surgery, radiation and chemotherapy, which can be effective initially, but the time to recurrence is relatively short for these cancers and survival prognosis is extremely poor following recurrence. New treatment options are urgently needed and an advanced immunotherapy approaches holds significant promise.
TapImmune’s clinical candidates have been validated in Phase I studies and fully vetted by industry and clinical leaders. The company is developing its programs in strategic collaboration with Mayo Clinic, Memorial Sloan Kettering Cancer Center, and AstraZeneca, and with significant non-dilutive funding from the U.S. Department of Defense. TapImmune’s novel vaccine candidate, TPIV 200, has been granted both Orphan Drug and FDA Fast Track Designation for treating ovarian cancer and is also eligible for Fast Track Designation for triple-negative breast cancer.